ZA200300701B - Methods for using tetanus toxin for beneficial purposes in animals (mammals). - Google Patents
Methods for using tetanus toxin for beneficial purposes in animals (mammals). Download PDFInfo
- Publication number
- ZA200300701B ZA200300701B ZA200300701A ZA200300701A ZA200300701B ZA 200300701 B ZA200300701 B ZA 200300701B ZA 200300701 A ZA200300701 A ZA 200300701A ZA 200300701 A ZA200300701 A ZA 200300701A ZA 200300701 B ZA200300701 B ZA 200300701B
- Authority
- ZA
- South Africa
- Prior art keywords
- tetanus toxin
- selected site
- effective amount
- therapeutically effective
- units
- Prior art date
Links
- 108010055044 Tetanus Toxin Proteins 0.000 title claims description 385
- 229940118376 tetanus toxin Drugs 0.000 title claims description 383
- 238000000034 method Methods 0.000 title claims description 161
- 241001465754 Metazoa Species 0.000 title claims description 105
- 230000009286 beneficial effect Effects 0.000 title description 17
- 241000124008 Mammalia Species 0.000 title description 14
- 210000003205 muscle Anatomy 0.000 claims description 143
- 210000002569 neuron Anatomy 0.000 claims description 110
- 230000000694 effects Effects 0.000 claims description 105
- 230000007423 decrease Effects 0.000 claims description 82
- 210000000056 organ Anatomy 0.000 claims description 75
- 238000002347 injection Methods 0.000 claims description 71
- 239000007924 injection Substances 0.000 claims description 71
- 210000005036 nerve Anatomy 0.000 claims description 69
- 230000001537 neural effect Effects 0.000 claims description 61
- 210000001519 tissue Anatomy 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000006870 function Effects 0.000 claims description 43
- 230000001413 cellular effect Effects 0.000 claims description 41
- 208000024891 symptom Diseases 0.000 claims description 40
- 230000001965 increasing effect Effects 0.000 claims description 39
- 210000002161 motor neuron Anatomy 0.000 claims description 39
- 210000005070 sphincter Anatomy 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 230000002401 inhibitory effect Effects 0.000 claims description 33
- 210000003491 skin Anatomy 0.000 claims description 30
- 230000002964 excitative effect Effects 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 28
- 239000002858 neurotransmitter agent Substances 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000004044 response Effects 0.000 claims description 26
- 230000028327 secretion Effects 0.000 claims description 26
- 210000004907 gland Anatomy 0.000 claims description 21
- 210000004877 mucosa Anatomy 0.000 claims description 20
- 210000003169 central nervous system Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 210000004379 membrane Anatomy 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 210000003296 saliva Anatomy 0.000 claims description 18
- 210000002460 smooth muscle Anatomy 0.000 claims description 18
- 208000036071 Rhinorrhea Diseases 0.000 claims description 17
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 17
- 208000005392 Spasm Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 230000002889 sympathetic effect Effects 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 16
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 108090000189 Neuropeptides Proteins 0.000 claims description 15
- 210000001097 facial muscle Anatomy 0.000 claims description 15
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims description 15
- 230000036407 pain Effects 0.000 claims description 15
- 230000002685 pulmonary effect Effects 0.000 claims description 15
- 201000004384 Alopecia Diseases 0.000 claims description 14
- 206010062575 Muscle contracture Diseases 0.000 claims description 14
- 208000006111 contracture Diseases 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 14
- 210000003097 mucus Anatomy 0.000 claims description 14
- 208000019695 Migraine disease Diseases 0.000 claims description 13
- 206010041235 Snoring Diseases 0.000 claims description 13
- 208000024963 hair loss Diseases 0.000 claims description 13
- 230000003676 hair loss Effects 0.000 claims description 13
- 229940088597 hormone Drugs 0.000 claims description 13
- 239000005556 hormone Substances 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 13
- 210000001044 sensory neuron Anatomy 0.000 claims description 13
- 230000001713 cholinergic effect Effects 0.000 claims description 12
- 210000002307 prostate Anatomy 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 12
- 210000003932 urinary bladder Anatomy 0.000 claims description 12
- 206010028735 Nasal congestion Diseases 0.000 claims description 11
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
- 239000002502 liposome Substances 0.000 claims description 11
- 206010027599 migraine Diseases 0.000 claims description 11
- 208000026451 salivation Diseases 0.000 claims description 11
- 206010039722 scoliosis Diseases 0.000 claims description 11
- 201000002859 sleep apnea Diseases 0.000 claims description 11
- 206010002153 Anal fissure Diseases 0.000 claims description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims description 10
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 10
- 208000014181 Bronchial disease Diseases 0.000 claims description 10
- 206010006482 Bronchospasm Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 208000004350 Strabismus Diseases 0.000 claims description 10
- 230000002638 denervation Effects 0.000 claims description 10
- 210000000609 ganglia Anatomy 0.000 claims description 10
- 230000006058 immune tolerance Effects 0.000 claims description 10
- 201000001881 impotence Diseases 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 206010028417 myasthenia gravis Diseases 0.000 claims description 10
- 210000002850 nasal mucosa Anatomy 0.000 claims description 10
- 230000002485 urinary effect Effects 0.000 claims description 10
- 208000000289 Esophageal Achalasia Diseases 0.000 claims description 9
- 206010030136 Oesophageal achalasia Diseases 0.000 claims description 9
- 206010044074 Torticollis Diseases 0.000 claims description 9
- 201000000621 achalasia Diseases 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 9
- 210000004211 gastric acid Anatomy 0.000 claims description 9
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 201000006938 muscular dystrophy Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 210000001187 pylorus Anatomy 0.000 claims description 9
- 210000002027 skeletal muscle Anatomy 0.000 claims description 9
- 210000001913 submandibular gland Anatomy 0.000 claims description 9
- 238000012384 transportation and delivery Methods 0.000 claims description 9
- 208000016583 Anus disease Diseases 0.000 claims description 8
- 208000014094 Dystonic disease Diseases 0.000 claims description 8
- 206010063006 Facial spasm Diseases 0.000 claims description 8
- 208000009531 Fissure in Ano Diseases 0.000 claims description 8
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 8
- 206010020880 Hypertrophy Diseases 0.000 claims description 8
- 206010028289 Muscle atrophy Diseases 0.000 claims description 8
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims description 8
- 208000013142 Writer cramp Diseases 0.000 claims description 8
- 206010005159 blepharospasm Diseases 0.000 claims description 8
- 230000000744 blepharospasm Effects 0.000 claims description 8
- 206010006514 bruxism Diseases 0.000 claims description 8
- 230000001079 digestive effect Effects 0.000 claims description 8
- 201000002865 focal hand dystonia Diseases 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 230000008105 immune reaction Effects 0.000 claims description 8
- 230000001771 impaired effect Effects 0.000 claims description 8
- 208000018197 inherited torticollis Diseases 0.000 claims description 8
- 210000002200 mouth mucosa Anatomy 0.000 claims description 8
- 230000020763 muscle atrophy Effects 0.000 claims description 8
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 239000002581 neurotoxin Substances 0.000 claims description 8
- 231100000618 neurotoxin Toxicity 0.000 claims description 8
- 210000003681 parotid gland Anatomy 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 201000002849 spasmodic dystonia Diseases 0.000 claims description 8
- 210000003670 sublingual gland Anatomy 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- 210000001942 upper esophageal sphincter Anatomy 0.000 claims description 8
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 claims description 7
- 206010013952 Dysphonia Diseases 0.000 claims description 7
- 208000001953 Hypotension Diseases 0.000 claims description 7
- 206010028836 Neck pain Diseases 0.000 claims description 7
- 206010030184 Oesophageal spasm Diseases 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 7
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 210000002808 connective tissue Anatomy 0.000 claims description 7
- 210000003890 endocrine cell Anatomy 0.000 claims description 7
- 210000001508 eye Anatomy 0.000 claims description 7
- 230000036543 hypotension Effects 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 210000000258 minor salivary gland Anatomy 0.000 claims description 7
- 230000008929 regeneration Effects 0.000 claims description 7
- 238000011069 regeneration method Methods 0.000 claims description 7
- 230000002123 temporal effect Effects 0.000 claims description 7
- 210000001541 thymus gland Anatomy 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 210000002453 autonomic neuron Anatomy 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 101710138657 Neurotoxin Proteins 0.000 claims description 4
- 210000003780 hair follicle Anatomy 0.000 claims description 4
- 230000007794 irritation Effects 0.000 claims description 4
- 230000008058 pain sensation Effects 0.000 claims description 4
- 210000001732 sebaceous gland Anatomy 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 210000002159 anterior chamber Anatomy 0.000 claims description 2
- 210000001156 gastric mucosa Anatomy 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000002741 palatine tonsil Anatomy 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 description 34
- 239000003053 toxin Substances 0.000 description 33
- 108700012359 toxins Proteins 0.000 description 33
- 108030001720 Bontoxilysin Proteins 0.000 description 26
- 229940053031 botulinum toxin Drugs 0.000 description 23
- 230000002567 autonomic effect Effects 0.000 description 21
- 206010043376 Tetanus Diseases 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000001734 parasympathetic effect Effects 0.000 description 17
- 230000009885 systemic effect Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 210000003050 axon Anatomy 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000001953 sensory effect Effects 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 102000005917 R-SNARE Proteins Human genes 0.000 description 7
- 108010005730 R-SNARE Proteins Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000003518 presynaptic effect Effects 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000035900 sweating Effects 0.000 description 7
- 210000000225 synapse Anatomy 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000033952 Paralysis flaccid Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000028331 flaccid paralysis Diseases 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000007441 retrograde transport Effects 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 210000003403 autonomic nervous system Anatomy 0.000 description 5
- 210000000467 autonomic pathway Anatomy 0.000 description 5
- 210000005056 cell body Anatomy 0.000 description 5
- 210000002939 cerumen Anatomy 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000030214 innervation Effects 0.000 description 5
- 230000002232 neuromuscular Effects 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 239000005526 vasoconstrictor agent Substances 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 4
- 101710151321 Melanostatin Proteins 0.000 description 4
- 102400000064 Neuropeptide Y Human genes 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000003843 mucus production Effects 0.000 description 4
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 4
- 210000002856 peripheral neuron Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000001584 soft palate Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 210000002820 sympathetic nervous system Anatomy 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000001944 turbinate Anatomy 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010020852 Hypertonia Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000003815 abdominal wall Anatomy 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 210000002932 cholinergic neuron Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000000613 ear canal Anatomy 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 210000001352 masseter muscle Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 description 3
- 238000002278 reconstructive surgery Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- ZNMXKJDERFMXNF-ZETCQYMHSA-N (1r)-1-(2-hydroxy-1,3,2-benzodioxaborol-5-yl)-2-(methylamino)ethanol Chemical compound CNC[C@H](O)C1=CC=C2OB(O)OC2=C1 ZNMXKJDERFMXNF-ZETCQYMHSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102100038518 Calcitonin Human genes 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010050337 Cerumen impaction Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010013142 Disinhibition Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102400000097 Neurokinin A Human genes 0.000 description 2
- 101800000399 Neurokinin A Proteins 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- 206010041415 Spastic paralysis Diseases 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229960000404 epinephryl borate Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000001983 hard palate Anatomy 0.000 description 2
- 201000000615 hard palate cancer Diseases 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036736 holocrine secretion Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001847 jaw Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 230000018052 penile erection Effects 0.000 description 2
- 210000001184 pharyngeal muscle Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 229960005367 tetanus antitoxin Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000001121 vomeronasal organ Anatomy 0.000 description 2
- HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010069493 Perennial allergy Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 231100001102 clostridial toxin Toxicity 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000003823 hyoid bone Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005072 internal anal sphincter Anatomy 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 231100000568 intoxicate Toxicity 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004717 laryngeal muscle Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002988 lumbosacral plexus Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010539 reproductive behavior Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 206010043378 tetanus neonatorum Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21456900P | 2000-06-28 | 2000-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300701B true ZA200300701B (en) | 2005-05-09 |
Family
ID=22799588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300701A ZA200300701B (en) | 2000-06-28 | 2003-01-27 | Methods for using tetanus toxin for beneficial purposes in animals (mammals). |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7494661B2 (es) |
| EP (1) | EP1365800B1 (es) |
| JP (1) | JP2004521067A (es) |
| AU (1) | AU2001270219A1 (es) |
| CA (1) | CA2413301A1 (es) |
| IL (1) | IL153734A0 (es) |
| MX (1) | MXPA03000014A (es) |
| WO (1) | WO2002000172A2 (es) |
| ZA (1) | ZA200300701B (es) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220266B2 (en) | 2000-05-19 | 2007-05-22 | C. R. Bard, Inc. | Tissue capturing and suturing device and method |
| IL153734A0 (en) * | 2000-06-28 | 2003-07-06 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| US7737109B2 (en) | 2000-08-11 | 2010-06-15 | Temple University Of The Commonwealth System Of Higher Education | Obesity controlling method |
| WO2002013854A1 (en) | 2000-08-11 | 2002-02-21 | Temple University Of The Commonwealth System Of Higher Education | Obesity controlling method |
| JP2005538983A (ja) * | 2002-07-19 | 2005-12-22 | メステックス アクチエンゲゼルシャフト | 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法 |
| EP1545207B1 (en) | 2002-08-19 | 2018-03-14 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| CA2854831C (en) | 2002-11-21 | 2016-08-30 | Ira Sanders | Treatment of mammalian reaction to ige interactions |
| WO2004076634A2 (en) | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| WO2004078199A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of chronic chalazion and hordeolum with botulinum toxin |
| EP1599220B1 (en) * | 2003-03-06 | 2013-07-17 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
| US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| CA2938411C (en) | 2003-09-12 | 2019-03-05 | Minnow Medical, Llc | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
| US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| WO2006068970A2 (en) | 2004-12-21 | 2006-06-29 | Mitchell Roslin | Anastomotic outlet revision |
| US7736392B2 (en) * | 2005-04-28 | 2010-06-15 | Medtronic, Inc. | Bulking of upper esophageal sphincter for treatment of obesity |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| US12433837B2 (en) | 2005-07-22 | 2025-10-07 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
| US7608275B2 (en) | 2005-07-22 | 2009-10-27 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
| US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| WO2008024879A1 (en) * | 2006-08-25 | 2008-02-28 | University Of Maryland, Baltimore | Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment |
| EP2076194B1 (en) | 2006-10-18 | 2013-04-24 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
| EP2992850A1 (en) | 2006-10-18 | 2016-03-09 | Vessix Vascular, Inc. | Inducing desirable temperature effects on body tissue |
| AU2007310988B2 (en) | 2006-10-18 | 2013-08-15 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
| EP2081638A4 (en) * | 2006-11-03 | 2013-06-12 | Gep Technology Inc | APPARATUS AND METHODS FOR THE INVASIVE TREATMENT OF OBESITY |
| JP2008228701A (ja) * | 2007-03-23 | 2008-10-02 | Japan Science & Technology Agency | 組換えタンパク質イムノテタヌストキシン |
| US7829272B2 (en) | 2007-05-24 | 2010-11-09 | Nanotrope Inc. | Viral detection liposomes and method |
| ES2332628B1 (es) * | 2007-10-05 | 2011-01-24 | Universidad De Zaragoza | Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. |
| US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| WO2009137819A1 (en) | 2008-05-09 | 2009-11-12 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| US8868215B2 (en) | 2008-07-11 | 2014-10-21 | Gep Technology, Inc. | Apparatus and methods for minimally invasive obesity treatment |
| US8666498B2 (en) * | 2008-10-27 | 2014-03-04 | Serene Medical, Inc. | Treatment of headache |
| EP2355737B1 (en) | 2008-11-17 | 2021-08-11 | Boston Scientific Scimed, Inc. | Selective accumulation of energy without knowledge of tissue topography |
| WO2010085259A1 (en) * | 2009-01-26 | 2010-07-29 | Nanotrope, Inc. | Viral detection liposomes and method |
| CN102639077B (zh) | 2009-10-27 | 2015-05-13 | 赫莱拉公司 | 具有可冷却的能量发射组件的递送装置 |
| JP2013510193A (ja) * | 2009-11-09 | 2013-03-21 | サンダース，イラ | 神経毒を用いる睡眠呼吸障害の処置 |
| KR101820542B1 (ko) | 2009-11-11 | 2018-01-19 | 호라이라 인코포레이티드 | 조직을 치료하고 협착을 제어하기 위한 방법, 기구 및 장치 |
| US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
| WO2011066285A2 (en) * | 2009-11-24 | 2011-06-03 | Oregon Health & Science University | Peptide-based treatment for neurodegenerative diseases |
| US20120251576A1 (en) * | 2009-12-15 | 2012-10-04 | Ira Sanders | Treatment of Nasal and Sinus Disorders |
| KR20130108067A (ko) | 2010-04-09 | 2013-10-02 | 베식스 바스큘라 인코포레이티드 | 조직 치료를 위한 발전 및 제어 장치 |
| US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
| US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
| US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
| US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
| US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
| US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
| US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
| US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
| US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
| US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
| US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
| US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
| US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
| US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
| US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
| US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
| US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
| WO2012100095A1 (en) | 2011-01-19 | 2012-07-26 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
| CN103813745B (zh) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | 用以可视化、对准和消融神经的经皮装置及方法 |
| JP6106669B2 (ja) | 2011-07-22 | 2017-04-05 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | ヘリカル・ガイド内に配置可能な神経調節要素を有する神経調節システム |
| US9186210B2 (en) | 2011-10-10 | 2015-11-17 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
| EP2765940B1 (en) | 2011-10-11 | 2015-08-26 | Boston Scientific Scimed, Inc. | Off-wall electrode device for nerve modulation |
| US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
| US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
| US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| WO2013059202A1 (en) | 2011-10-18 | 2013-04-25 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
| EP2775948B1 (en) | 2011-11-08 | 2018-04-04 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
| US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
| US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
| US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
| WO2013096922A1 (en) | 2011-12-23 | 2013-06-27 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
| EP2797534A1 (en) | 2011-12-28 | 2014-11-05 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
| US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
| US10737123B2 (en) | 2012-03-08 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
| AU2013230776B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Immune system neuromodulation and associated systems and methods |
| US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
| CN104540465A (zh) | 2012-08-24 | 2015-04-22 | 波士顿科学西美德公司 | 带有含单独微孔隙区域的球囊的血管内导管 |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014043687A2 (en) | 2012-09-17 | 2014-03-20 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
| US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
| US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
| WO2014059165A2 (en) | 2012-10-10 | 2014-04-17 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| CN109044528B (zh) | 2013-01-31 | 2021-11-02 | 迪格玛医疗有限公司 | 用于减少受试者的器官中的神经活性的方法和系统 |
| US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
| WO2014143571A1 (en) | 2013-03-11 | 2014-09-18 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
| US9297845B2 (en) | 2013-03-15 | 2016-03-29 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
| CN105473090B (zh) | 2013-03-15 | 2019-05-03 | 波士顿科学国际有限公司 | 重建身体通道的组织或邻近身体通道的组织的方法及装置 |
| US9943365B2 (en) | 2013-06-21 | 2018-04-17 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
| JP2016524949A (ja) | 2013-06-21 | 2016-08-22 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 回転可能シャフトを有する腎神経アブレーション用医療装置 |
| US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
| EP3016605B1 (en) | 2013-07-01 | 2019-06-05 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
| CN105377170A (zh) | 2013-07-11 | 2016-03-02 | 波士顿科学国际有限公司 | 具有可伸展电极组件的医疗装置 |
| US10660698B2 (en) | 2013-07-11 | 2020-05-26 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
| US9925001B2 (en) | 2013-07-19 | 2018-03-27 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
| EP3024405A1 (en) | 2013-07-22 | 2016-06-01 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
| WO2015013205A1 (en) | 2013-07-22 | 2015-01-29 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
| JP6159888B2 (ja) | 2013-08-22 | 2017-07-05 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 腎神経変調バルーンへの接着性を向上させたフレキシブル回路 |
| CN105555218B (zh) | 2013-09-04 | 2019-01-15 | 波士顿科学国际有限公司 | 具有冲洗和冷却能力的射频(rf)球囊导管 |
| WO2015038947A1 (en) | 2013-09-13 | 2015-03-19 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
| US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
| EP3057488B1 (en) | 2013-10-14 | 2018-05-16 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
| AU2014334574B2 (en) | 2013-10-15 | 2017-07-06 | Boston Scientific Scimed, Inc. | Medical device balloon |
| US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
| JP6259099B2 (ja) | 2013-10-18 | 2018-01-10 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 可撓性を備える導電性ワイヤを備えるバルーン・カテーテル、並びに関連する使用および製造方法 |
| WO2015061457A1 (en) | 2013-10-25 | 2015-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
| WO2015103617A1 (en) | 2014-01-06 | 2015-07-09 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
| US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
| CN106572881B (zh) | 2014-02-04 | 2019-07-26 | 波士顿科学国际有限公司 | 热传感器在双极电极上的替代放置 |
| US10537387B2 (en) | 2014-04-17 | 2020-01-21 | Digma Medical Ltd. | Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum |
| EP3164149A1 (en) * | 2014-07-02 | 2017-05-10 | Spherium Biomed S.L. | Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc) |
| JP2017536187A (ja) | 2014-12-03 | 2017-12-07 | メタベンション インコーポレイテッド | 神経または他の組織を調節するためのシステムおよび方法 |
| JP2019511505A (ja) | 2016-03-31 | 2019-04-25 | ゴジョ・インダストリーズ・インコーポレイテッド | 抗菌ペプチド刺激性清浄組成物 |
| US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| JP2019510037A (ja) | 2016-03-31 | 2019-04-11 | ゴジョ・インダストリーズ・インコーポレイテッド | 抗菌ペプチド刺激性洗浄組成物 |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| US10575904B1 (en) | 2016-08-14 | 2020-03-03 | Digma Medical Ltd. | Apparatus and method for selective submucosal ablation |
| EP3496800B1 (en) | 2016-08-14 | 2020-11-04 | Digma Medical Ltd. | Apparatus for nerve ablation in the wall of the gastointestinal tract |
| WO2018098152A1 (en) | 2016-11-23 | 2018-05-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| CN120661638A (zh) * | 2018-07-31 | 2025-09-19 | 斯诺雷托克斯私人有限公司 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
| EP3843777A4 (en) | 2018-08-28 | 2022-05-04 | Ira Sanders | THERAPEUTICS FOR THE SKIN |
| US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
| US12246024B2 (en) | 2019-12-13 | 2025-03-11 | Free State Pharma Inc | Compositions and methods for controlling cerumen production |
| CN117244043B (zh) * | 2023-11-02 | 2024-09-20 | 徐州医科大学附属医院 | 破伤风类毒素在治疗血管内皮细胞损伤中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5053005A (en) * | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| ATE215832T1 (de) * | 1994-05-09 | 2002-04-15 | William J Binder | Botulinumtoxin zur reduktion von migraine - kopfschmerzen |
| US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5897579A (en) * | 1994-09-15 | 1999-04-27 | Mount Sinai School Of Medicine | Method of relieving airway obstruction in patients with bilateral vocal impairment |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| DK0773788T3 (da) * | 1995-06-06 | 2003-09-01 | Allergan Inc | Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| WO1999037326A1 (en) * | 1998-01-26 | 1999-07-29 | University Of Massachusetts | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| DK1084146T3 (da) * | 1998-05-13 | 2003-02-03 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf |
| CA2347828A1 (en) * | 1998-10-27 | 2000-05-04 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
| GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| US7838007B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US6500436B2 (en) * | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| IL153734A0 (en) * | 2000-06-28 | 2003-07-06 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| AU2002320127A1 (en) * | 2001-06-21 | 2003-01-08 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| DE10153950A1 (de) * | 2001-11-06 | 2003-05-22 | Bayer Ag | Wasserdampfdurchlässiger Beschichtungsverbund |
| EP1545207B1 (en) * | 2002-08-19 | 2018-03-14 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7666435B2 (en) * | 2002-08-19 | 2010-02-23 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| US20040037895A1 (en) * | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
| CA2501856A1 (en) * | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| CA2854831C (en) * | 2002-11-21 | 2016-08-30 | Ira Sanders | Treatment of mammalian reaction to ige interactions |
| WO2004076634A2 (en) * | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| PT1802339E (pt) * | 2004-09-23 | 2011-12-15 | Toxcure Inc | Tratamento de neoplasmas com neurotoxina |
| WO2010011597A2 (en) * | 2008-07-22 | 2010-01-28 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
-
2001
- 2001-06-28 IL IL15373401A patent/IL153734A0/xx unknown
- 2001-06-28 US US10/312,705 patent/US7494661B2/en not_active Expired - Fee Related
- 2001-06-28 JP JP2002504955A patent/JP2004521067A/ja active Pending
- 2001-06-28 EP EP01948786A patent/EP1365800B1/en not_active Expired - Lifetime
- 2001-06-28 WO PCT/US2001/020523 patent/WO2002000172A2/en not_active Ceased
- 2001-06-28 AU AU2001270219A patent/AU2001270219A1/en not_active Abandoned
- 2001-06-28 MX MXPA03000014A patent/MXPA03000014A/es active IP Right Grant
- 2001-06-28 CA CA002413301A patent/CA2413301A1/en not_active Abandoned
-
2003
- 2003-01-27 ZA ZA200300701A patent/ZA200300701B/en unknown
-
2008
- 2008-10-16 US US12/288,077 patent/US8834897B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2413301A1 (en) | 2002-01-03 |
| IL153734A0 (en) | 2003-07-06 |
| WO2002000172A2 (en) | 2002-01-03 |
| EP1365800A2 (en) | 2003-12-03 |
| EP1365800B1 (en) | 2013-03-06 |
| US8834897B2 (en) | 2014-09-16 |
| MXPA03000014A (es) | 2004-09-13 |
| AU2001270219A1 (en) | 2002-01-08 |
| WO2002000172A3 (en) | 2003-08-07 |
| US20040248188A1 (en) | 2004-12-09 |
| EP1365800A4 (en) | 2005-08-10 |
| US20090060953A1 (en) | 2009-03-05 |
| JP2004521067A (ja) | 2004-07-15 |
| US7494661B2 (en) | 2009-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7494661B2 (en) | Methods for using tetanus toxin for beneficial purposes in animals (mammals) | |
| JP4249802B2 (ja) | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ | |
| US9504735B2 (en) | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease | |
| US6986893B2 (en) | Method for treating a mucus secretion | |
| US6896886B2 (en) | Use of botulinum toxins for treating various disorders and conditions and associated pain | |
| EP1790352B1 (en) | Use of botulinum toxin for the manufacture of a medicament for reducing low back pain | |
| US8187612B2 (en) | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle | |
| US8557256B2 (en) | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin | |
| AU2007203272A1 (en) | Methods for Using Tetanus Toxin for Beneficial Purposes in Animals (Mammals) | |
| CA2300703C (en) | Method for treating excessive sweating | |
| HK1106700B (en) | Use of botulinum toxin for the manufacture of a medicament for reducing low back pain |